title: [Do we know all effects of heparins in hemodialyzed patients?].
abstract: Anticoagulation with heparins during hemodialysis (HD) is aimed at preventing the activation of coagulation in the extracorporeal circuit. As HD patients are exposed to unfractionated and low molecular weight heparins (LMWH) for years, non-hemorrhagic effects (osteoporosis, reduction of elevated blood pressure, with lesser intra- and interdialytic hypotensive episodes, effects on brain microvascular circulation and decreasing vascular dementia and Alzheimer's disease, and chronic and malignant diseases) require new trials with individualized doses of heparins.
authors: Split University Hospital Center, Department of Nephrology and Dialysis, School of Medicine, University of Split, Split, Croatia. milenkas@net.hr
authors: Milenka
authors: M
authors: Sain
authors: Dragan
authors: D
authors: Ljutić
authors: Vedran
authors: V
authors: Kovacić
authors: Josipa
authors: J
authors: Radić
authors: Ivo
authors: I
authors: Jelicić
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006435:Renal Dialysis
chemical_list: D000925:Anticoagulants; D006493:Heparin